Cargando…

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring

In this study, 48 inhibitors were docked to 107 allosteric centers of human immunodeficiency virus 1 (HIV-1) reverse transcriptase from the Protein Data Bank (PDB). Based on the average binding scores, quantitative structure-activity relationship (QSAR) equations were constructed in order to elucida...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paneth, Agata, Płonka, Wojciech, Paneth, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631718/ https://www.ncbi.nlm.nih.gov/pubmed/31022835 http://dx.doi.org/10.3390/ph12020064

Ejemplares similares

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
por: Paneth, Agata, et al.
Publicado: (2017)

A Search for Dual Action HIV-1 Reverse Transcriptase, Bacterial RNA Polymerase Inhibitors
por: Paneth, Agata, et al.
Publicado: (2017)

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Sluis-Cremer, Nicolas
Publicado: (2014)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

N(1),N(3)-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
por: Novikov, Mikhail S., et al.
Publicado: (2013)

Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein–Human ACE2 Receptor Interface
por: Płonka, Wojciech, et al.
Publicado: (2020)

Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility
por: Frączek, Tomasz, et al.
Publicado: (2017)

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2023)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Antibacterial Activity of Fluorobenzoylthiosemicarbazides and Their Cyclic Analogues with 1,2,4-Triazole Scaffold
por: Kosikowska, Urszula, et al.
Publicado: (2020)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha, Yu-Jung, et al.
Publicado: (2014)

Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors
por: Liu, Genyan, et al.
Publicado: (2018)

Machine Learning augmented docking studies of aminothioureas at the SARS-CoV-2—ACE2 interface
por: Rola, Monika, et al.
Publicado: (2021)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Karamchand, Sumanth, et al.
Publicado: (2016)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Influence of Association on Binding of Disaccharides to YKL-39 and hHyal-1 Enzymes
por: Krzemińska, Agnieszka, et al.
Publicado: (2022)

Isotopic Consequences of Host–Guest Interactions; Noncovalent Chlorine Isotope Effects
por: Paneth, Agata, et al.
Publicado: (2021)

4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-Toxoplasma gondii agents
por: Bekier, Adrian, et al.
Publicado: (2021)

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

1,4-Disubstituted Thiosemicarbazide Derivatives are Potent Inhibitors of Toxoplasma gondii Proliferation
por: Dzitko, Katarzyna, et al.
Publicado: (2014)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Unprecedently large (37)Cl/(35)Cl equilibrium isotopic fractionation on nano-confinement of chloride anion
por: Pokora, Mateusz, et al.
Publicado: (2022)

Non-Covalent Isotope Effects
por: Pokora, Mateusz, et al.
Publicado: (2023)

Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains
por: Liu, Yongjian, et al.
Publicado: (2020)

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
por: Brown, Jennifer A., et al.
Publicado: (2021)

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
por: Bertagnolio, Silvia, et al.
Publicado: (2020)

Retrospective analysis of the HIV-1 reverse transcriptase inhibitors’ resistance in Silesia, Poland
por: Smolen, Joanna, et al.
Publicado: (2011)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Approved HIV reverse transcriptase inhibitors in the past decade
por: Li, Guangdi, et al.
Publicado: (2022)

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase
por: Nakamura, Akiyoshi, et al.
Publicado: (2015)

Thiosemicarbazide Derivatives Decrease the ATPase Activity of Staphylococcus aureus Topoisomerase IV, Inhibit Mycobacterial Growth, and Affect Replication in Mycobacterium smegmatis
por: Kowalczyk, Aleksandra, et al.
Publicado: (2021)

RNA-Inspired and Accelerated Degradation of Polylactide in Seawater
por: Rheinberger, Timo, et al.
Publicado: (2021)

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
por: Ilina, Tatiana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hlseca0vjoiltfn45eb2ucqstp